Todos os estudos
RecrutamentoFASE3INTERVENCIONISTA

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

This study is for adults with a condition called Immune Thrombocytopenia (ITP). ITP causes your body to destroy tiny blood cells called platelets, which help your blood clot. This can lead to bruising and bleeding easily. We are trying to find out if a new medicine called mezagitamab can help keep platelet counts stable in people with ITP. Participants will receive either mezagitamab or a dummy medicine (placebo) by injection under the skin for up to 6 months. We then look at how each group's platelet counts change. Some people might also have the chance to continue taking mezagitamab after the main study ends.

Em resumo

Status
Recrutamento
Fase
FASE3
Patrocinador
Takeda
Meta de inscrição
171
Iniciar
27 Fev 2025
Conclusão estimada
16 Mar 2028

Sobre o que é este estudo?

This study is focused on a condition called Immune Thrombocytopenia, or ITP. If you have ITP, your body's defence system, called the immune system, mistakenly attacks and destroys your platelets. Platelets are really important because they are tiny cells in your blood that help it to clot and stop bleeding. When you don't have enough platelets, you might bruise easily, notice small red spots on your skin, or experience nosebleeds or gum bleeding.

We are looking into a new medicine called mezagitamab. The main goal of this study is to see if mezagitamab can effectively help keep your platelet count at a healthy and stable level compared to a placebo. A placebo looks exactly like the real medicine but doesn't contain any active ingredients. This helps us understand if any improvements are truly due to the new medicine.

Participants in the study will receive mezagitamab or the placebo as an injection just under the skin. This treatment will continue for up to six months. We hope this study will give us important information about whether mezagitamab could be a helpful new treatment option for people living with ITP.

Pontos principais

  • This study is testing a new medicine (mezagitamab) for adults with ITP.
  • It aims to see if mezagitamab can help keep platelet counts stable.
  • You might receive the new medicine or a dummy treatment (placebo).
  • Treatment is given by injection under the skin for up to 6 months.
  • Regular clinic visits are required to monitor your health.
  • There's a chance to continue with mezagitamab after the main study, if eligible.

Quem pode ser elegível?

This study is for adults aged 18 and over who have been diagnosed with ITP for at least a year. You would need to have shown a good response to an ITP treatment in the past (but not a type called a TPO-RA), and your current platelet count should be less than 30,000.

You also need to have tried and not responded well to or couldn't tolerate at least two different types of ITP treatment – one first-line treatment (like steroids) and at least one second-line treatment (like TPO-RAs, rituximab, fostamatinib, or mycophenolate). If you're using other ITP treatments, they need to have been at a steady dose for at least a month before the study starts and expected to stay the same throughout.

You wouldn't be able to join if your ITP is due to another medical condition (called secondary ITP), if you've had a blood clot or stroke in the last year, have had your spleen removed, or have certain active infections like Hepatitis B, C, or HIV. A history of certain cancers would also mean you couldn't take part.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Tenho 18 anos ou mais.
  2. I have been diagnosed with ITP for at least one year.
  3. My current platelet count is less than 30,000.
  4. I have tried at least two different ITP treatments (like steroids and another type) in the past, and they either didn't work well enough or caused too many side effects.
  5. I have not had a blood clot or stroke in the past year.
  6. I do not have Hepatitis B, C, or HIV.
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join the study, you'll receive the study medicine (mezagitamab or a placebo) as an injection under your skin for up to 6 months. Throughout this time, you'll need to visit the study clinic several times. These visits will involve checks to see how you are doing, including blood tests to measure your platelet count and general health. The doctors will also ask you questions about any side effects you might be experiencing.

After the main study finishes, or if the treatment doesn't seem to be working for you after 16 weeks, you may get the chance to join a follow-on study. In this continuation study, eligible participants would receive mezagitamab openly, meaning they would know they are getting the active medicine. The doctors will explain more about this if it applies to you.

Riscos e benefícios potenciais

Taking part in a clinical trial can have potential benefits, like gaining access to a new medicine before it's widely available, and helping doctors learn more about ITP and its treatment. However, there are also potential risks, such as side effects from the medicine or the extra clinic visits required. You might receive the placebo, which means you won't get the active study drug. Your health will be carefully monitored throughout the study, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (124)

  • Genesis Cancer and Blood Institute - SCRI
    Código postal verificado
    Hot Springs, Estados Unidos· Recrutamento
  • USC Norris Comprehensive Cancer Center - Keck Medicine of USC
    Código postal verificado
    Los Angeles, Estados Unidos· Recrutamento
  • University of California San Diego Center for Bleeding and Clotting Disorders
    Código postal verificado
    San Diego, Estados Unidos· Ainda não recrutando
  • Rocky Mountain Cancer Center
    Código postal verificado
    Denver, Estados Unidos· Retirado
  • Georgetown University Medical Center - Lombardi Comprehensive Cancer Center
    Código postal verificado
    Washington D.C., Estados Unidos· Recrutamento
  • Universidade Emory
    Código postal verificado
    Atlanta, Estados Unidos· Recrutamento
  • Innovative Hematology, Inc.
    Código postal verificado
    Indianápolis, Estados Unidos· Recrutamento
  • The University of Iowa
    Código postal verificado
    Iowa City, Estados Unidos· Recrutamento
  • University Of Louisville Brown Cancer Center
    Código postal verificado
    Louisville, Estados Unidos· Recrutamento
  • American Oncology Partners of Maryland, PA
    Código postal verificado
    Bethesda, Estados Unidos· Recrutamento
  • Hospital Geral de Massachusetts
    Código postal verificado
    Boston, Estados Unidos· Recrutamento
  • University of Massachusetts Chan Medical School
    Código postal verificado
    Worcester, United States· Concluído

Perguntas frequentes

What is ITP?

ITP (Immune Thrombocytopenia) is a condition where your immune system mistakenly destroys your platelets, which are tiny cells that help your blood clot. This can lead to easy bruising and bleeding.

What is mezagitamab?

Mezagitamab is the new medicine being tested in this study. We want to see if it can help keep platelet counts stable in people with ITP.

O que é um placebo?

A placebo is a dummy medicine. It looks exactly like the study medicine but contains no active ingredients. It helps doctors work out if the real medicine is having an effect.

How will I receive the study medicine?

The study medicine (mezagitamab or placebo) will be given as an injection just under your skin.

Quanto tempo estarei no estudo?

You will receive the study medicine for up to 6 months, and there will be several follow-up visits during and after this period.

Como saber mais

Contato Takeda

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study of Mezagitamab in Adults With Chronic Primary Immune…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.